Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination

Journal of Dermatological Science

Volumn 53, Issue 1, 2009, Pages 40-47

  Nakai, Noriaki ^a   Katoh, Norito ^a   Germeraad, Wilfred T V ^b   Kishida, Tsunao ^a   Ueda, Eiichiro ^a   Takenaka, Hideya ^a   Mazda, Osam ^a   Kishimoto, Saburo ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Delayed type hypersensitivity; Dendritic cell vaccination; Immunohistological analysis; Melanoma; Melanoma antigen

Indexed keywords

CD1D ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; DENDRITIC CELL VACCINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; T6 ANTIGEN; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DERMIS; EOSINOPHIL; ERYTHEMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOHISTOLOGY; INJECTION SITE; MALE; MELANOMA; MONOCYTE; MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SKIN BIOPSY; SUBCUTANEOUS TISSUE; TH1 CELL; TH2 CELL;

AGED; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; BIOPSY; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; LANGERHANS CELLS; MALE; MELANOMA; MIDDLE AGED; SKIN; SKIN NEOPLASMS; TH1 CELLS; TH2 CELLS; TIME FACTORS;

EID: 57549086472     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2008.07.013     Document Type: Article

References (41)

1. Ishihara K., Saida T., Yamamoto A., and Otsuka F. Nationwide survey of malignant skin tumors (1997-2001). Skin Cancer (Japan) 19 (2004) 147-155
2. Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4 (1998) 328-332
3. Morisaki T., Matsumoto K., Onishi H., Kuroki H., Baba E., Tasaki A., et al. Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives. Hum Cell 16 (2003) 175-182
4. Mazda O., and Germeraad W.T.V. Tumor immunity and immuno-gene therapy of malignancies. In: Mazda O. (Ed). Frontiers in immuno-gene therapy (2004), Research Signpost, Trivandrum 1-30
5. Nakai N., Asai J., Ueda E., Takenaka H., Katoh N., and Kishimoto S. Vaccination of Japanese patients with advanced melanoma with peptide, tumor lysate or both peptide and tumor lysate-pulsed mature, monocyte-derived dendritic cells. J Dermatol 33 (2006) 462-472
6. Chakraborty N.G., Chattopadhyay S., Mehrotra S., Chhabra A., and Mukherji B. Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma. Hum Immunol 65 (2004) 794-802
7. Berger T.G., Haendle I., Schrama D., Luftl M., Bauer N., Pedersen L.O., et al. Circulation and homing of melanoma-reactive T cells to both cutaneous and visceral metastases after vaccination with monocyte-derived dendritic cells. Int J Cancer 111 (2004) 229-237
8. Shu S., Cochran A.J., Huang R.R., Morton D.L., and Maecker H.T. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy. Cancer Metastasis Rev 25 (2006) 233-242
9. Jager E., Jager D., and Knuth A. CTL-defined cancer vaccines: perspectives for active immunotherapeutic interventions in minimal residual disease. Cancer Metastasis Rev 18 (1999) 143-150
10. Jager D., Jager E., and Knuth A. Vaccination for malignant melanoma: recent developments. Oncology 60 (2001) 1-7
11. Jager D., Jager E., and Knuth A. Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J Clin Pathol 54 (2001) 669-674
12. de Vries I.J., Bernsen M.R., Lesterhuis W.J., Scharenborg N.M., Strijk S.P., Gerritsen M.J., et al. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 23 (2005) 5779-5787
13. van den Eertwegh A.J. Active specific immunotherapy in colon cancer. Recent Results Cancer Res 165 (2005) 260-267
14. Bedrosian I., Mick R., Xu S., Nisenbaum H., Faries M., Zhang P., et al. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients. J Clin Oncol 21 (2003) 3826-3835
15. Roosje P.J., van Kooten P.J., Thepen T., Bihari I.C., Rutten V.P., Koeman J.P., et al. Increased numbers of CD4+ and CD8+ T cells in lesional skin of cats with allergic dermatitis. Vet Pathol 35 (1998) 268-273
16. Dannenberg Jr. A.M. Roles of cytotoxic delayed-type hypersensitivity and macrophage-activating cell-mediated immunity in the pathogenesis of tuberculosis. Immunobiology 191 (1994) 461-473
17. Adams L.G. In vivo and in vitro diagnosis of Mycobacterium bovis infection. Rev Sci Tech 20 (2001) 304-324
18. Frew A.J., Varney V.A., Gaga M., and Kay A.B. Immunohistology of human allergic late-phase skin reactions. Skin Pharmacol 4 Suppl. 1 (1991) 71-78
19. Gaga M., Frew A.J., Varney V.A., and Kay A.B. Eosinophil activation and T lymphocyte infiltration in allergen-induced late phase skin reactions and classical delayed-type hypersensitivity. J Immunol 147 (1991) 816-822
20. Tsicopoulos A., Fahy O., and Tonnel A.B. Delayed-type hypersensitivity reactions to nominal protein antigens and to environmental allergens: similarities and differences. Eur J Dermatol 9 (1999) 261-268
21. Eguchi J., Hiroishi K., Ishii S., Baba T., Matsumura T., Hiraide A., et al. Interleukin-4 gene transduced tumor cells promote a potent tumor-specific Th1-type response in cooperation with interferon-alpha transduction. Gene Ther 12 (2005) 733-741
22. Poulter L.W., Seymour G.J., Duke O., Janossy G., and Panayi G. Immunohistological analysis of delayed-type hypersensitivity in man. Cell Immunol 74 (1982) 358-369
23. Platt J.L., Grant B.W., Eddy A.A., and Michael A.F. Immune cell populations in cutaneous delayed-type hypersensitivity. J Exp Med 158 (1983) 1227-1242
24. Chu C.Q., Field M., Andrew E., Haskard D., Feldmann M., and Maini R.N. Detection of cytokines at the site of tuberculin-induced delayed-type hypersensitivity in man. Clin Exp Immunol 90 (1992) 522-529
25. Janossy G., Panayi G., Duke O., Bofill M., Poulter L.W., and Goldstein G. Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immunoregulation. Lancet 2 (1981) 839-842
26. De Vries I.J., Bernsen M.R., van Geloof W.L., Scharenborg N.M., Lesterhuis W.J., Rombout P.D., et al. In situ detection of antigen-specific T cells in cryo-sections using MHC class I tetramers after dendritic cell vaccination of melanoma patients. Cancer Immunol Immunother (2007)
27. Gerlini G., Hefti H.P., Kleinhans M., Nickoloff B.J., Burg G., and Nestle F.O. Cd1d is expressed on dermal dendritic cells and monocyte-derived dendritic cells. J Invest Dermatol 117 (2001) 576-582
28. Seino K., Motohashi S., Fujisawa T., Nakayama T., and Taniguchi M. Natural killer T cell-mediated antitumor immune responses and their clinical applications. Cancer Sci 97 (2006) 807-812
29. Yang D., Chen Q., Rosenberg H.F., Rybak S.M., Newton D.L., Wang Z.Y., et al. Human ribonuclease A superfamily members, eosinophil-derived neurotoxin and pancreatic ribonuclease, induce dendritic cell maturation and activation. J Immunol 173 (2004) 6134-6142
30. Yang D., Rosenberg H.F., Chen Q., Dyer K.D., Kurosaka K., and Oppenheim J.J. Eosinophil-derived neurotoxin (EDN), an antimicrobial protein with chemotactic activities for dendritic cells. Blood 102 (2003) 3396-3403
31. Grewe M., Czech W., Morita A., Werfel T., Klammer M., Kapp A., et al. Human eosinophils produce biologically active IL-12: implications for control of T cell responses. J Immunol 161 (1998) 415-420
32. Woerly G., Roger N., Loiseau S., Dombrowicz D., Capron A., and Capron M. Expression of CD28 and CD86 by human eosinophils and role in the secretion of type 1 cytokines (interleukin 2 and interferon gamma): inhibition by immunoglobulin a complexes. J Exp Med 190 (1999) 487-495
33. Bandeira-Melo C., Sugiyama K., Woods L.J., Phoofolo M., Center D.M., Cruikshank W.W., et al. IL-16 promotes leukotriene C(4) and IL-4 release from human eosinophils via CD4- and autocrine CCR3-chemokine-mediated signaling. J Immunol 168 (2002) 4756-4763
34. Gessner A., Mohrs K., and Mohrs M. Mast cells, basophils, and eosinophils acquire constitutive IL-4 and IL-13 transcripts during lineage differentiation that are sufficient for rapid cytokine production. J Immunol 174 (2005) 1063-1072
35. Kita H., Ohnishi T., Okubo Y., Weiler D., Abrams J.S., and Gleich G.J. Granulocyte/macrophage colony-stimulating factor and interleukin 3 release from human peripheral blood eosinophils and neutrophils. J Exp Med 174 (1991) 745-748
36. Shurin M.R., Lu L., Kalinski P., Stewart-Akers A.M., and Lotze M.T. Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin Immunopathol 21 (1999) 339-359
37. Ronger-Savle S., Valladeau J., Claudy A., Schmitt D., Peguet-Navarro J., Dezutter-Dambuyant C., et al. TGFbeta inhibits CD1d expression on dendritic cells. J Invest Dermatol 124 (2005) 116-118
38. Zou W., and Regulatory. T cells, tumour immunity and immunotherapy. Nat Rev Immunol 6 (2006) 295-307
39. Kageshita T., Wang Z., Calorini L., Yoshii A., Kimura T., Ono T., et al. Selective loss of human leukocyte class I allospecificities and staining of melanoma cells by monoclonal antibodies recognizing monomorphic determinants of class I human leukocyte antigens. Cancer Res 53 (1993) 3349-3354
40. Limpens J., Garssen J., Germeraad W.T., and Scheper R.J. Enhancing effects of locally administered cytostatic drugs on T effector cell functions in mice. Int J Immunopharmacol 12 (1990) 77-88
41. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441 (2006) 235-238